Scynexis(SCYX)

Focus: Scynexis is a public biotechnology company focused on small molecule treatments for infectious diseases and respiratory conditions, particularly fungal infections. The company operates at a mid-cap scale with a publicly traded status (NASDAQ: SCYX).

Infectious Diseases Respiratory

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Scynexis

AI assessmentNot Hiring

No open roles listed right now. Follow Scynexis to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Late-stage

7 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$4M

Key Products

Ibrexafungerp

Vulvovaginal Candidiasis, Invasive Candidiasis, Candida Vulvovaginitis

Growth

Lead asset in Phase 3 across three indication areas with potential for multiple approvals.

SCY-078

Invasive Candidiasis, Mycoses, Vulvovaginal Candidiasis, Invasive Pulmonary Aspergillosis

Help build intelligence for Scynexis

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Leading pipeline in antifungal therapy with 7 Phase 3 programs including Ibrexafungerp for multiple candidiasis indications
Public company status provides equity visibility and potential liquidity events
Focused therapeutic area (infectious diseases/mycology) offers deep specialization opportunity

Watch Out For

Severe revenue collapse year-over-year (FY2024: $140M to FY2025: $4M) signals major commercial setback or asset divestiture
Cash position of $16M is critically low for a biotech with $26M annual R&D spend, raising 12-18 month runway concerns
Zero open job postings indicates possible hiring freeze or company contraction

Generated by Claude from Scynexis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Broad-spectrum Phase 2/3 candidate addressing multiple fungal infection indications.

Pipeline & Clinical Trials

Non-interventional study

Vulvovaginal Candidiasis

N/A

Clinical Trials (1)

NCT05908682Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes

N/A

[14C]-Ibrexafungerp

Fungal Infection

PHASE_1

Clinical Trials (1)

NCT04307082ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects

Phase 1

DAB

Pharmacokinetics

PHASE_1

Clinical Trials (1)

NCT04092725Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects

Phase 1

PRA

Pharmacokinetics

PHASE_1

Clinical Trials (1)

NCT04092751Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects

Phase 1

Ibrexafungerp

Fungal Disease

PHASE_1

Clinical Trials (1)

NCT05668429ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects

Phase 1

Ibrexafungerp

Vulvovaginal Candidiasis

PHASE_1

Clinical Trials (1)

NCT06954493Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp

Phase 1

Placebo

Chronic Hepatitis C

PHASE_1

Clinical Trials (1)

NCT01290965Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients

Phase 1

Placebo

Hepatitis C Infection

PHASE_2

Clinical Trials (1)

NCT01265511Study of SCY-635, Pegasys and Copegus in Hepatitis C

Phase 2

SCY-078

Invasive Pulmonary Aspergillosis

PHASE_2

Clinical Trials (1)

NCT03672292Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis

Phase 2

SCY-078

Mycoses

PHASE_2

Clinical Trials (1)

NCT02244606Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

Phase 2

SCY-078

Vulvovaginal Candidiasis

PHASE_2

Clinical Trials (1)

NCT02679456Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis

Phase 2

Fluconazole

Candida Vulvovaginitis

PHASE_2

Clinical Trials (1)

NCT03253094Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

Phase 2

Ibrexafungerp

Vulvovaginal Candidiasis

PHASE_3

Clinical Trials (1)

NCT05399641Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

Phase 3

SCY-078

Candidiasis, Invasive

PHASE_3

Clinical Trials (1)

NCT03363841Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)

Phase 3

SCY-078

Candidiasis, Invasive

PHASE_3

Clinical Trials (1)

NCT05178862A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Phase 3

Ibrexafungerp

Invasive Candidiasis

PHASE_3

Clinical Trials (1)

NCT03059992Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

Phase 3

Ibrexafungerp

Candida Vulvovaginitis

PHASE_3

Clinical Trials (1)

NCT03987620Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

Phase 3

Fluconazole Tablet

Recurrent Vulvovaginal Candidiasis

PHASE_3

Clinical Trials (1)

NCT04029116Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)

Phase 3

Ibrexafungerp

Candida Vulvovaginitis

PHASE_3

Clinical Trials (1)

NCT03734991Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 19 clinical trials

Top TAs: Infectious Diseases, Respiratory

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Infectious Diseases

2 pipeline

Respiratory

2 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$4M97%

R&D Spend

$26M(705%)15%

Net Income

-$21M